Electra Therapeutics
PublicElectra Therapeutics is now publicly traded
The data on this page reflects Electra Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series C
Oct 22, 2025
Est. Valuation at Exit
$479M
Total Funding Raised
$267M
Company Overview
Electra Therapeutics operates in Biotech and is based in South San Francisco, California. It has raised $267M.
Electra Therapeutics is a biotechnology company developing antibody therapies that target signal regulatory proteins to treat immunological diseases and cancer.
Sector
Biotech
Verticals
Life Sciences, Oncology
AI Layer
Non-AI
Electra Therapeutics Comparables
Compare Electra Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ALX Oncology | 84% | |
| Biosion, Inc. | 81% | |
| Alector | 78% |
For institutional investors. Book with your work email.
Electra Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 22, 2025 | ||||
| Series B | Feb 16, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Electra Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B, Series C |
| RA Capital Management | Series C, Series B |
| New Leaf Venture Partners | Series C, Series B |
| EQT Life Sciences | Series C |
| Westlake Village BioPartners | Series C, Series B |
| Cowen Private Investments | Series B |
| Cormorant Asset Management | Series C, Series B |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 4, 2026
Electra Therapeutics Inc. plans to present at the 2026 Jefferies Global Healthcare Conference in the United Kingdom on Nov 18th '26.
- hiresSep 23, 2026
Electra Therapeutics Inc. designates Carl L. Gordon to serve on its board, according to a filing.
- receives_financingSep 18, 2026
Electra Therapeutics Inc. receives $350M in an upsized IPO in United States on Sep 18th '26.
- is_developingSep 10, 2026
Electra Therapeutics Inc. develops ELA822, a novel SIRPγ-specific monoclonal antibody designed to selectively deplete activated, pathogenic T cells, and initiates its Phase 1 trial in healthy volunteers in California on Sep 10th '26.
- promotesSep 9, 2026
In California on Sep 9th '26, Electra Therapeutics Inc. promotes Chris Clark, CFA, to Chief Financial Officer from Executive Vice President, Strategy and Finance, a role he holds since joining the company in December 2025.
For institutional investors. Book with your work email.
Electra Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.